NASDAQ$IDXX

IDEXX Laboratories Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported revenue growth and EPS growth, driven by Companion Animal Group Diagnostics recurring revenue growth.

IDEXX Laboratories reported Q2 2021 revenues of $826 million, a 30% increase, with EPS of $2.34, a 36% increase. The company also increased its 2021 revenue and EPS guidance.

  • Reported revenue growth of 30% and organic revenue growth of 25%, driven by CAG Diagnostics recurring revenue growth of 30% as reported and 26% organic
  • Delivered EPS of $2.34, representing 36% growth as reported and 33% on a comparable basis
  • Increased 2021 revenue guidance to $3,170 million - $3,205 million, reflecting higher expectations for reported growth of 17% - 18.5% and organic growth of 14.5% - 16%, supported by projected CAG Diagnostics recurring revenue growth of 18% - 19.5% as reported and 16% - 17.5% organic
  • Raised 2021 EPS outlook to $8.20 - $8.36, reflecting an increase of 1% - 1.5% in the organic revenue growth outlook and expectations for higher operating margins of 28.6% - 29.1%

Headline financials

Total Revenue

$826M

Previous: $638M+29.6%
EPS (adj)

$2.34

Previous: $1.72+36.0%
Capital Expenditures

-$42.7M

Previous: -$73.6M+41.9%
Free Cash Flow

$160M

Previous: $75.4M+112.0%
Net Income

$203M

Previous: $149M+36.0%
Operating Income

$259M

Previous: $193M+34.2%
Gross Profit

$489M

Previous: $379M+29.0%
Cash & Equivalents

$232M

Previous: $105M+120.5%
Total Assets

$2.41B

Previous: $1.96B+23.0%
Stock-Based Comp

$9.64M

Previous: $7.8M+23.6%

Revenue & EPS history

IDEXX · Revenue · Quarterly

$826M

Q2 2021+29.6%vs Q2 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

IDEXX · $826M total across 9 segments · Q2 2021

  • Reference labs
    $294M
  • VetLab consumables
    $256M
  • Rapid assay products
    $83.9M
  • Vet software & imaging
    $49.2M
  • Water
    $37.2M+32.3%
  • Dx capital instruments
    $35.1M
  • LPD
    $33.5M+4.0%
  • Dx services & accessories
    $27.4M
  • Other
    $9.83M-11.7%

Forward guidance

IDEXX provided full year 2021 guidance for revenue between $3,170 million and $3,205 million and EPS between $8.20 and $8.36.

Tailwinds

  • Revenue $3,170-$3,205 million
  • Reported growth 17%-18.5%
  • Organic growth 14.5%-16%
  • CAG Diagnostics Recurring Revenue Growth Reported growth 18%-19.5%
  • CAG Diagnostics Recurring Revenue Organic growth 16%-17.5%

Headwinds

  • Operating Margin 28.6%-29.1%
  • Operating margin expansion 290-340 bps
  • Comparable margin expansion 175-225 bps
  • EPS $8.20-$8.36
  • Reported EPS growth 22%-25%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.7%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+2.8%

Avg return

30 days after

43%

30 / 69 earnings

Positive

+27.5%

Q2 2025

Best reaction

-18.9%

Q1 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.4%-0.6%-0.1%
Q4 2025-4.8%-3.9%-3.2%
Q3 2025+14.9%+12.5%+15.3%
Q2 2025+27.5%+22.9%+18.4%
Q1 2025+9.0%+9.5%+18.7%
Q4 2024+11.1%+8.9%+3.6%
Q3 2024-7.5%-7.8%-6.5%
Q2 2024+2.6%+6.1%+3.1%
Q1 2024-3.4%-3.2%+0.9%
Q4 2023+7.6%+8.5%+5.8%
Q3 2023+5.0%+5.9%+20.8%
Q2 2023-6.4%-9.1%-7.8%
Q1 2023-2.2%-0.2%-4.0%
Q4 2022+5.2%+0.7%-0.0%
Q3 2022+3.6%+3.4%+22.1%
Q2 2022+2.2%+2.4%-12.1%
Q1 2022-11.7%-20.9%-14.5%
Q4 2021+5.0%+0.8%+4.3%
Q3 2021-6.1%-4.4%-10.1%
Q2 2021-3.6%-0.8%-5.1%
Q1 2021-3.6%-1.0%+0.1%
Q4 2020-1.4%+2.1%-1.3%
Q3 2020+0.5%+5.0%+7.4%
Q2 2020+4.8%+5.8%+2.6%
Q1 2020-0.7%+3.4%+13.3%
Q4 2019-2.8%-3.3%-10.3%
Q3 2019+1.1%-3.5%-8.1%
Q2 2019-4.7%-4.1%+2.7%
Q1 2019+4.5%+8.6%+7.7%
Q4 2018-4.5%-1.9%+1.5%
Q3 2018-3.4%-4.6%-3.9%
Q2 2018-1.7%-0.8%+3.7%
Q1 2018+6.0%+5.5%+10.0%
Q4 2017-0.4%-3.7%-0.7%
Q3 2017-3.1%-5.4%-4.9%
Q2 2017-9.2%-8.3%-6.6%
Q1 2017+0.6%-1.5%+2.9%
Q4 2016+15.7%+16.6%+19.8%
Q3 2016-1.6%-0.9%+6.6%
Q2 2016+15.5%+16.6%+21.0%
Q1 2016+5.6%
Q4 2015+10.4%
Q3 2015-8.8%
Q2 2015+9.4%
Q1 2015-18.9%
Q4 2014-3.1%
Q3 2014+9.8%
Q2 2014-2.7%
Q1 2014+2.9%
Q4 2013+6.5%
Q3 2013-1.0%
Q2 2013-0.6%
Q1 2013-6.4%
Q4 2012-3.5%
Q3 2012-1.1%
Q2 2012-5.3%
Q1 2012-3.4%
Q4 2011-0.5%
Q3 2011+3.2%
Q2 2011+6.3%
Q1 2010+0.0%
Q1 2011+3.0%
Q4 2008-3.9%
Q4 2010-3.9%
Q3 2009-1.4%
Q3 2010-1.4%
Q4 2009-2.7%
Q2 2009-2.7%
Q2 2010-2.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro